English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Chemospecificity and cross-reactivity of target cell recognition by human CD56+ NK and LAK cells

MPS-Authors
/persons/resource/persons282684

Zhu,  H-G
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons76245

Voetsch,  W
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons284481

Hauer,  J
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

/persons/resource/persons282624

Anderer,  FA
Anderer Group, Friedrich Miescher Laboratory, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Zhu, H.-G., Voetsch, W., Hauer, J., & Anderer, F. (1995). Chemospecificity and cross-reactivity of target cell recognition by human CD56+ NK and LAK cells. Scandinavian Journal of Immunology, 41(6), 545-552. doi:10.1111/j.1365-3083.1995.tb03606.x.


Cite as: https://hdl.handle.net/21.11116/0000-000C-0FA2-D
Abstract
Inhibition of specific cytotoxicity of highly purified (> 95%) human CD56+ NK and LAK cells against K562 tumour cells was studied with various sugar acetates. Maximum inhibitory specificity was obtained with 60%-deacetylated penta-acetates of mannose, galactose, glucose, or 80%-deacetylated penta-O-acetate of N-acetyl neuraminic acid. The inhibition was strictly dosedependent and 100% inhibition was achieved in the concentration range of 500-1000 nmoles/ml with all four sugar acetate samples. Enhancement of specific cytotoxicity in the presence of rhamnogalacturonan (RG; 500 ng/ml), acting as a bridging molecule, was also inhibited in a dose-dependent manner with the same inhibitory specificity and within the same concentration range indicating involvement of the same number of sugar acetate-specific receptors. Moreover, formation of lytic CD56+ effector cell/tumour cell (E/T) conjugates was equally well inhibited whereas formation of total E/T conjugates was only partially inhibited (NK: 44-73%; LAK: 46-50%). E/T conjugate formation in the presence of RG was enhanced. Inhibition of the enhancement of formation of lytic E/T conjugates in the presence of RG was again completely accomplished with the same inhibitory specificity and within the same concentration ranges as recorded for E/T conjugate formation in the absence of RG. However, inhibition of total E/T conjugate formation was again only partially achieved at the given concentrations. The data support the assumption of an NK cell receptor with specificity for acetylated carbohydrate moieties on target cells or on bridging molecules such as RG.